{ "docId": "019de516-01ce-701d-bd9b-acac15fa9fab", "docSlug": "a13be9775a99db49a0c5c2ac3ee2ea88", "documentTitle": "Oculis | Investor Conference Presentation Deck | 39 slides", "authorId": "oculis", "authorName": "Oculis", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-06-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "pageCount": 39, "prevPage": 31, "nextPage": 33, "slideType": "propose_solution", "function": "propose_solution", "density": "overcrowded", "nDataPoints": 20, "notes": null, "elementsJson": null, "metadataConfidence": 0.9, "imagePath": null, "slideHref": "/slides/019de516-01ce-701d-bd9b-acac15fa9fab/32", "deckHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab", "deckJsonHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab.json", "deckAnchorHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab#slide-32", "components": [ { "bbox": { "h": 0.22, "w": 0.33, "x": 0.039, "y": 0.34 }, "kind": "chart", "text": "Eyedrops RGCs count/20x field Sham control Glaucoma NGF (200µg/ml) OCS-05 (200µg/ml) OCS-05 (400µg/ml) % of Efficacy 82.1 81.7 77.1", "attrs": null, "subkind": "bar-vertical", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "4bc723d2-b4cd-44e2-b4bc-ad09f125d5f2", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.22, "w": 0.33, "x": 0.039, "y": 0.59 }, "kind": "chart", "text": "Intravitreal Nt RGCs/20X field Sham control Glaucoma OCS-05 % of Efficacy 96.3", "attrs": null, "subkind": "bar-vertical", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "a4bb08cc-db99-49f8-b506-20bbf97918ae", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.55, "w": 0.3, "x": 0.67, "y": 0.33 }, "kind": "chart", "text": "Clinical assessment (score) Severe disabilities Treatment initiation Placebo OCS-05 50 mpk OCS-05 100 mpk Experimental Autoimmune Encephalomyelitis model in mice", "attrs": null, "subkind": "line", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "8ddef719-ced1-4126-b6ab-e8a2d32299b0", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.68, "w": 0.24, "x": 0.399, "y": 0.26 }, "kind": "image", "text": "Visual of RGC Protection Sham control RGC Placebo Loss of RGC OCS-05 70 mg/kg More RGC remain", "attrs": null, "subkind": "illustration", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "202f2fb4-acb1-4c29-885e-238be2477d2b", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.015, "w": 0.29, "x": 0.683, "y": 0.309 }, "kind": "list", "text": "OCS-05 | Model of autoimmune AON and MS(5)", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "6033938f-6b07-4fa8-9361-c6124b2bece9", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.015, "w": 0.31, "x": 0.04, "y": 0.309 }, "kind": "list", "text": "OCS-05 | H&E(4) for RGC density at week 6(5)", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "d89df50a-f2d2-4ad4-a020-168e2c28702e", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.05, "w": 0.27, "x": 0.683, "y": 0.199 }, "kind": "paragraph", "text": "OCS-05 shown to promote improvement of clinical function (disability) in experimental autoimmune encephalomyelitis (EAE) model", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "069205f3-ee95-486a-9460-5d9cd560de58", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.24, "x": 0.399, "y": 0.2 }, "kind": "paragraph", "text": "AON model: Short term study (5-day treatment, assessment at day 6)", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "b983ac29-63d9-4d4f-8b65-3d4cd450f593", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.33, "x": 0.037, "y": 0.199 }, "kind": "paragraph", "text": "OCS-05, IVT and topical, shown to prevent RGC(3) damage (the key element in Glaucoma vision loss)", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "bb5d8c40-bbe5-48eb-a984-1b9af59ad1b3", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.33, "x": 0.037, "y": 0.84 }, "kind": "paragraph", "text": "High-pressure Glaucoma rat model of neurodegeneration without inflammation", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "ef0db158-5131-43ca-93ce-cdb6d65985dd", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.06, "w": 0.35, "x": 0.025, "y": 0.91 }, "kind": "source-note", "text": "(1) Primary Open-Angle Glaucoma (POAG). (2) Experimental autoimmune encephalomyelitis (EAE). (3) Retinal ganglion cell (RGC). (4) Hematoxylin and eosin (H&E) staining. (5) Villoslada P. et al. Neurotherapeutics, published online: 27 February 2019.", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f4cc346b-8a95-4626-acf7-df35ea09260e", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.027, "w": 0.75, "x": 0.025, "y": 0.089 }, "kind": "title", "text": "Compelling data showing prevention of RGC damage in Glaucoma and AON models", "attrs": null, "subkind": "action-title", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "bdb9ac99-3b54-4f15-9f1b-18feefd664cf", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.62, "x": 0.025, "y": 0.044 }, "kind": "title", "text": "OCS-05 | Neuro-ophthalmology Candidate", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f4046336-523b-4ceb-8f77-344b37961955", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [ { "name": "Before-After-Bridge", "slug": "before-after-bridge", "agent": "Storyteller", "layer": "slide", "matchId": "f5f4e1f5-697b-48a3-ac3c-e48e78ba88e5", "evidence": "chart/bar-vertical: Eyedrops RGCs count/20x field Sham control Glaucoma NGF (200µg/ml) OCS-05 (200µg/ml) OCS-05 (400µg/ml) % of Efficacy 82.1 81.7 77.1", "confidence": 0.8 }, { "name": "Waterfall chart", "slug": "waterfall-chart", "agent": null, "layer": "slide", "matchId": "b02a5a73-734f-418a-92db-3f66d283bcd5", "evidence": "chart/line: Clinical assessment (score) Severe disabilities Treatment initiation Placebo OCS-05 50 mpk OCS-05 100 mpk Experimental Autoimmune Encephalomyelitis model in mice", "confidence": 0.7 } ], "frameworks": [], "arcBeats": [ { "to": 39, "from": 25, "beatId": "6cce666b-f795-4a3e-a589-afe2a7266ece", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Slides 25-39 discuss OCS-02, OCS-05, and the track record of efficient capital deployment.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }